Top Stories
NX210c reduced plasma levels of Claudin 5, a biomarker of blood-brain barrier dysfunction.
JNJ-5120/PIPE-307 failed to improve Montgomery-Åsberg Depression Rating Scale (MADRS) total score compared with placebo in patients with major depressive disorder.
The Treg-focused company raised $44 million in a series A from Playground, and also pocketed a $22-million award from Japan’s Agency for Medical Research and Development.
The company is pressing ahead with a dual combination therapy for cystic fibrosis (CF) after SION-719 disappointed in a Phase II trial last month.
The US regulator will also pilot reviewing IND submissions on a rolling basis.
Conference News
A close look at Phase III DESTINY-Lung04 results raises questions about where AZ and Daiichi Sankyo's Enhertu will fit into the treatment algorithm for HER2+ NSCLC.
PARIS, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics (“Egle”), a clinical-stage biotechnology company advancing a proprietary therapeutic pipeline targeting T cell (Treg) modulation, announced ...
Presentation highlights data demonstrating that the dual LSD1/HDAC6 inhibitor achieves rapid and sustained dose-responsive reductions in platelet counts in patients with essential thrombocythemia (ET)...
– Top-line, prespecified analysis in patients with unmethylated MGMT newly diagnosed glioblastoma (ndGBM) suggests clinically meaningful improvement in overall survival, preservation of neurological f...
TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative musc...
